MARKET

MBIO

MBIO

Mustang Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.915
+0.045
+2.41%
Opening 14:51 12/06 EST
OPEN
1.880
PREV CLOSE
1.870
HIGH
1.935
LOW
1.800
VOLUME
816.20K
TURNOVER
--
52 WEEK HIGH
5.22
52 WEEK LOW
1.800
MARKET CAP
178.91M
P/E (TTM)
-2.2564
1D
5D
1M
3M
1Y
5Y
Mustang Bio EPS misses by $0.01
Mustang Bio (NASDAQ:MBIO): Q3 GAAP EPS of -$0.19 misses by $0.01. Revenue of $0M Press Release As of September 30, 2021, Mustang’s cash and cash equivalents and restricted cash totaled
Seekingalpha · 11/12 13:27
BRIEF-Mustang Bio Reports Q3 Loss Per Share Of $0.19
reuters.com · 11/12 13:14
Mustang Bio Q3 EPS $(0.19) Up From $(0.23) YoY
Mustang Bio (NASDAQ:MBIO) reported quarterly losses of $(0.19) per share. This is a 17.39 percent increase over losses of $(0.23) per share from the same period last year.
Benzinga · 11/12 13:09
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologi...
GlobeNewswire · 11/12 13:05
-- Earnings Flash (MBIO) MUSTANG BIO Posts Q3 Loss $-0.19
MT Newswires · 11/12 08:09
Mustang Bio Signs License Agreement with Leiden University Medical Centre for Gene Therapy Candidate to Treat Immunodeficiency
MT Newswires · 11/10 09:46
Insider Buy: Mustang Bio
MT Newswires · 11/08 17:29
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
Key opinion leader webinar on Thursday, December 16, 2021, at 2:30 p.m. ET...
Globe Newswire · 11/04 13:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MBIO. Analyze the recent business situations of Mustang Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MBIO stock price target is 9.80 with a high estimate of 13.00 and a low estimate of 7.00.
High13.00
Average9.80
Low7.00
Current 1.915
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 110
Institutional Holdings: 30.83M
% Owned: 33.00%
Shares Outstanding: 93.43M
TypeInstitutionsShares
Increased
28
2.22M
New
7
665.13K
Decreased
26
1.64M
Sold Out
20
527.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.25%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
Chairman/Executive Director/Director
Michael Weiss
President/Chief Executive Officer/Director
Manuel Litchman
Senior Vice President - Finance/Controller
Brian Achenbach
Director
Lindsay Rosenwald
Independent Director
Adam Chill
Independent Director
Neil Herskowitz
Independent Director
Michael Zelefsky
No Data
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. Its MB-102 is a CD123 CAR T cell Program for blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Webull offers kinds of Mustang Bio Inc stock information, including NASDAQ:MBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBIO stock methods without spending real money on the virtual paper trading platform.